Human Papilloma Virus clinical trials

Explore recruiting human papilloma virus clinical trials.

Recruiting human papilloma virus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Papilloma Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A clinical study of the V540A vaccine in healthy adults (V540A-001)

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A clinical study of the V540C vaccine in healthy adults (V540C-003)

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

Slovakia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in 16- to 26-Year Old Women

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Human Papilloma Virus trials by city

Human Papilloma Virus in Toronto Human Papilloma Virus in Vancouver Human Papilloma Virus in Montreal Human Papilloma Virus in Calgary Human Papilloma Virus in Edmonton Human Papilloma Virus in Ottawa Human Papilloma Virus in Winnipeg Human Papilloma Virus in Quebec City Human Papilloma Virus in Hamilton Human Papilloma Virus in Kitchener Human Papilloma Virus in London Human Papilloma Virus in Halifax Human Papilloma Virus in New York Human Papilloma Virus in Los Angeles Human Papilloma Virus in Chicago Human Papilloma Virus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease